References to Specific Topics
Bettens K, Sleegers K, Van Broeckhoven C. Genetic insights in Alzheimer’s disease. Lancet Neurol. 2013;12:92–104.
Blau N, Hennermann JB, Langenbeck U, et al. Diagnosis, classification, and genetics of phenylketonuria and tetrahydrobiopterin (BH4) deficiencies. Mol Genet Metab. 2011;104:S2–S9.
Byers PH, Pyott SM. Recessively inherited forms of osteogenesis imperfecta. Ann Rev Genet. 2012;46:475–497.
Chamberlin JS. Duchenne muscular dystrophy models show their age. Cell. 2010;143:1040–1042.
Chillon M, Casals T, Mercier B, et al. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med. 1995;332:1475–1480.
Colak D, Zaninovic N, Cohen MS, et al. Promoter-bound trinucleotide repeat mRNA drives epigenetic silencing in fragile X syndrome. Science. 2014;343:1002–1005.
Cutting GR. Modifier genes in Mendelian disorders: the example of cystic fibrosis. Ann N Y Acad Sci. 2010;1214:57–69.
Flanigan KM. The muscular dystrophies. Semin Neurol. 2012;32:255–263.
Fong LG, Young SG. PCSK9 function and physiology. J Lipid Res. 2008;49:1152–1156.
Goldstein JL, Brown MS. Molecular medicine: the cholesterol quartet. Science. 2001;292:1310–1312.
Gu YY, Harley ITW, Henderson LB, et al. IFRD1 polymorphisms in cystic fibrosis with potential link to altered neutrophil function. Nature. 2009;458:1039–1042.
Janciauskiene SM, Bals R, Koczulla R, et al. The discovery of alpha1-antitrypsin and its role in health and disease. Respir Med. 2011;105:1129–1139.
Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature. 2012;488:96–99.
Kathiresan S, Melander O, Guiducci C, et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet. 2008;40:189–197.
Koopman WJ, Willems PH, Smeitink JA. Monogenic mitochondrial disorders. N Engl J Med. 2012;366:1132–1141.
Laine CM, Joeng KS, Campeau PM, et al. WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta. N Engl J Med. 2013;368:1809–1816.
Lopez CA, Cleary JD, Pearson CE. Repeat instability as the basis for human diseases and as a potential target for therapy. Nat Rev Mol Cell Biol. 2010;11:165–170.
Moskowitz SM, James F, Chmiel JF, et al. Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders. GeneTests. 2008;10:851–868.
Raal FJ, Santos ED. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012;223:262–268.
Ramsey BW, Banks-Schlegel S, Accurso FJ, et al. Future directions in early cystic fibrosis lung disease research: an NHLBI workshop report. Am J Respir Crit Care Med. 2012;185:887–892.
Schon EA, DiMauro S, Hirano M. Human mitochondrial DNA: roles of inherited and somatic mutations. Nat Rev Genet. 2012;13:878–890.
Selkoe DJ. Alzheimer’s disease. Cold Spring Harb Perspect Biol. 2011;3:a004457.
Sosnay PR, Siklosi KR, Van Goor F, et al. Defining the disease liability of mutations in the cystic fibrosis transmembrane conductance regulator gene. Nature Genet. 2013;45:1160–1167.
Vafai SB, Mootha VK. Mitochondrial disorders as windows into an ancient organelle. Nature. 2012;491:374–383.
Zoghbi HY, Orr HT. Pathogenic mechanisms of a polyglutamine-mediated neurodegenerative disease, spinocerebellar ataxia type 1. J Biol Chem. 2009;284:7425–7429.